TD Private Client Wealth LLC Sells 945 Shares of United Therapeutics Corporation $UTHR

TD Private Client Wealth LLC decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 21.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,436 shares of the biotechnology company’s stock after selling 945 shares during the period. TD Private Client Wealth LLC’s holdings in United Therapeutics were worth $1,674,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter worth about $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the period. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on UTHR. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $566.80 on Wednesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company’s 50 day moving average price is $561.48 and its two-hundred day moving average price is $509.54. The company has a market capitalization of $24.06 billion, a P/E ratio of 20.92, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the company earned $6.63 EPS. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. Analysts forecast that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 14,440 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 550,413 shares of company stock valued at $305,867,937. Company insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.